Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (41)	3/17/1998 8:02:00 AM
From: syfon	Respond to of 626

Thank you for information. I am looking forward to reading more. SYFON

To: Arthur Radley who wrote (41)	3/25/1998 3:58:00 PM
From: JFitnich	Read Replies (1) \| Respond to of 626

Something interesting I came across, in the 2 reports included in the company's packet, Everen figures about 16M to TTNP for the launch of Ilioperidone. Sturza is betting on 40M and a 10%royalty rate. Estimates are just guesses, I realize...but does Everen know something Sturza's gang dosen't? $24M is a large chunk of change for a company this size. If anybody has the info, I would like to know what G.K. Mattison thinks of all this. As far as I know the company hasn't stated what the royalty rate is. Thanks to anyone in advance. JF P.S. BTW I like Pivanex as the drug for this co. Ilioperidone is the $maker that will let these other drugs get through trials. My style is to invest in co.'s that keep stuffing decent drugs down the pipe and look for them to come out the other end.(Except for XOMA which I own and will probably own if the co. falls down a crevice.) I've digressed. Good Investing, JF